compounding of semaglutide Pharmacy Semaglutide: Deep Dive FDA Warns on Certain Forms

Announcing our partnership with CVS Caremark to redefine employer GLP-1 access

This is the challenge and opportunity we will be facing in a market-based reformation of health care in the U.S

Learn what 2025 research reveals.

In 2025, advanced medical options like Endoscopic Sleeve Gastroplasty (ESG), bariatric surgery, and GLP-1 medications offer powerful support beyond lifestyle changes.

Key highlights: Once-daily oral administration Up to 11.8% weight loss over 36 weeks Focus on broader cardiometabolic health outcomes Advancement into Phase III development As obesity remains one of the most significant global health challenges, innovation in oral GLP-1 therapies could help improve accessibility and patient adherence while expanding treatment options beyond injectable therapies